Stocks · News reference
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 5:28 PM
- Checked
- Jul 21, 2026, 5:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-researchModerna Borrows $2 Billion To Expand Oncology Business
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.
Read original at benzingaEXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.
Read original at benzingaMike Johnson Says Prescription Drug Prices Are at 'Lowest Levels' in 60 Years, Credits Trump and Republicans for Lower Costs
Johnson credits Trump and Republicans for record low drug prices, stating Americans are seeing lower costs and more money in their pockets.
Read original at benzinga